Tapering is best reserved for those in complete remission with stable disease for at least 6 months, although many individual patient characteristics must be taken into account, experts say.
Related Keywords
Paris , France General , France , National University Hospital , Singapore General , Singapore , Toronto , Ontario , Canada , Montreal , Quebec , Merck Serono , Dafnad Gladman , Danielj Wallace , Lyann Nguyen , Sasha Bernatsky , Nathalie Costedoat , Eli Lilly , Los Angeles , Bristol Myers Squibb , Jiacai Cho , Joant Merrill , James Mcgill , Glaxosmithkline , Statistics At Paris City University , Novartis , University Of Toronto , University Of Oklahoma Health Sciences Center , Amgen , Pfizer , National Referral Center , Mcgill University , Astrazeneca , Sinai Medical Center , Schroeder Arthritis Institute , Lancet Rheumatologyconcluded , Nathalie Costedoat Chalumeau , Rare Autoimmune , Systemic Diseases , Cochin Hospital , Paris City University , Lupus Low Disease Activity State , Activity Index , Physician Global Assessment , Toronto Lupus Cohort , Oklahoma Health Sciences Center , Oklahoma City , Cedars Sinai Medical Center , Systemic Lupus Erythematosus , Sale , Remission , Lupus , Corticosteroid , Toxicology , Glucocorticosteroids , Immunosuppressive Therapy , Immunosuppressive Agents , Immunosuppressive Drugs , Rug Immunosuppressive , Steroids , Patient Safety , Calcineurin Inhibitor , Hands , Hospitals , Oklahoma , Cardiovascular Imaging , Ardiac Imaging , V Imaging ,
comparemela.com © 2020. All Rights Reserved.